We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 22.25 | 151,007 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 22.00 | 22.50 | 22.25 | 22.25 | 22.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 30.8M | -21.7M | -0.0600 | -3.71 | 80.43M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:17:22 | O | 4,415 | 22.375 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/10/2024 | 07:00 | UK RNS | Creo Medical Group PLC Extension of Retail Offer Closing Date |
| 01/10/2024 | 13:34 | ALNC |  EARNINGS: Savannah Energy swings to profit; Creo loss widens |
| 01/10/2024 | 07:00 | UK RNS | Creo Medical Group PLC Result of Placing |
| 30/9/2024 | 15:50 | UK RNS | Creo Medical Group PLC Retail Offer for up to £5.0 million |
| 30/9/2024 | 15:46 | UK RNS | Creo Medical Group PLC Half-year Report |
| 30/9/2024 | 15:45 | UK RNS | Creo Medical Group PLC Proposed Placing, Launch of ABB, Retail Offer |
| 18/9/2024 | 12:00 | UK RNS | Creo Medical Group PLC Strategic Partnership & 51% subsidiary cash sale |
| 29/8/2024 | 11:05 | UK RNS | Creo Medical Group PLC Holding(s) in Company |
| 01/8/2024 | 07:00 | UK RNS | Creo Medical Group PLC Award of Shares under Share Incentive Plan |
| 02/7/2024 | 20:03 | ALNC | TRADING UPDATES: Creo extends contract; Belluscura raises funds |
Creo Medical (CREO) Share Charts1 Year Creo Medical Chart |
|
1 Month Creo Medical Chart |
Intraday Creo Medical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/10/2024 | 21:01 | Creo Medical Group PLC 2023 | 856 |
| 08/6/2023 | 16:55 | Creo Medical Group... 2017 | 623 |
| 03/12/2018 | 12:41 | First use of Speedboat in mainland Europe | - |
| 09/12/2016 | 14:52 | China Real Estate Opportunities | 3 |
| 27/6/2012 | 12:52 | having a look...... | 1,095 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 12/10/2024 09:20 by Creo Medical Daily Update Creo Medical Group Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker CREO. The last closing price for Creo Medical was 22.25p.Creo Medical currently has 361,476,442 shares in issue. The market capitalisation of Creo Medical is £80,428,508. Creo Medical has a price to earnings ratio (PE ratio) of -3.71. This morning CREO shares opened at 22.25p |
Posted at 02/10/2024 10:05 by dr biotech Will be interesting to see how much if anything is raised in the public offering. You'd think the answer would be 0, but there are always a few mugs about. I've followed the offers made through Primary bid - mostly but not entirely a list of barge pole companies wanting to raise money to pay their directors. One of them (BMN) offered the shares at 0.3p when the market buy price was something like 0.24 - and still raised a few tens of thousands. Their share price as of course dropped since then and anyone who took part on the placing is in the 90% club.Of course those who took part in the early placings here are sharing the same liferaft. --- To answer the previous question, the sale of the consumables business will result in a loss of about £1.5m of cash per year. That would of course push time to break even back a bit here, but according to their previous forecasts only by a year, if that. Its the lack of sales that has been the real issue and delayed forecast breakeven to 2028. It will also cause a huge slump in revenue as currently all creo revenue is counted and as they will become a minority holder I believe that will then drop the consumables revenue to zero. I'm not an accountant so I may be wrong. Obviously they would have their 49% holding that would get a dividend at 100% profit instead. The one possible saviour would be a deal with a kampative partner. When I was at the AGM I asked what did they need to really drive sales - the reply was clinical data. Whilst the ball is rolling its not going to be anytime soon. |
Posted at 20/9/2024 17:27 by dr biotech I'm generally against looking at single trades but there were 3 big sells at below the spread - I guess in a fairly illiquid stock that can be enough to move it. If cannacord or similar sold up then we will likely get an RNS next week.Results should be soon, I'm guessing the distribution business will have done OK as otherwise they wouldn't have got the seemingly good price for it. The key area will be the core own products. I'm not expecting fireworks, a good linear progression with a promising outlook and perhaps some news on how the ablation trial is progressing. I'm optomistic, but the lowly share price is a concern. |
Posted at 20/9/2024 17:09 by nimbo10 The shareprice action is bemusing, are market makers just playing to catch out those that bought on the RNS? there isn't that much volume for such downward move. With normal transactions going down, MM see opportunities in increasing volumes with company RNS and swings in share price. |
Posted at 18/9/2024 21:17 by dr biotech Yeah, whilst buying shares is always a risk, the major risk here has passed. Now they just have to prove they can sell their core products.I'm not on twitter, but some chinese guy has posted this (in chinese). Doesn't add a lot but its written from their point of view Nanwei Medical: Announcement on the purchase of 51% equity of Creo Medical S.L.U. [Sun] Basic situation: It is planned to use its own funds to purchase 51% equity of the target company CME through Nanwei Holland. The estimated transaction amount of this transaction is not more than 36.72 million euros (equivalent to approximately RMB 289.4821 million). After the completion of this transaction, the company will hold 51% equity of CME through Nanwei Holland. [Sun] Target company: A wholly-owned subsidiary of Creo, it is a channel company for the sales of medical device products. Its distribution products include Creo's self-developed products and medical device products in the fields of digestion, urology, respiratory, disposable endoscopes, etc. produced by other related medical device companies. Among them, endoscopic consumables and disposable endoscopes account for nearly 70% of the target company's revenue in 2023. The main business is concentrated in Western Europe, covering the United Kingdom, Spain, France, Germany, Belgium, Luxembourg and other countries. The revenue in 2023/2024H1 is 31.942 million/16.593 million euros, and the net profit is 3.468 million/1.574 million euros respectively. [Sun] Acquisition price: Combining the income method and the market value of the original shareholder Creo, the equity value of the target company is finally determined to be 72 million euros after friendly negotiation between the two parties. Valuation calculation: Referring to the content of the announcement, the PE of the target company in 2023 corresponding to this acquisition is about 21 times, and the PS is about 2.25 times. [Sun] Transaction funds: The funds for this transaction come from the company's own funds. As of June 30, 2024, the company's asset-liability ratio is 14.81%, and the company's monetary funds are 122,329.27 million yuan. The transaction amount accounts for about 23.66% of the company's monetary funds. |
Posted at 18/9/2024 12:44 by 74tom imjustdandyThe company is valued at £133m, they are going to get net proceeds of €30m (£25m) and have a remaining interest in Creo Europe of £30m. 55/133 is 41%, not 75%. It gives them breathing space financially, however they are losing pre tax profits of ~£1.8m and revenue of ~£14m from Creo Europe. Net net it's a positive, but the real value driver is growth rates in the original Creo endoscopy business. |
Posted at 27/8/2024 18:11 by innnovate I think it's worth pointing out that Joanne Hart recommended Creo at the time of the listing back in 2016.It was a good tip and happily I made money on it. However Creo came down hard from those highs. Looking back across the 8 years of public listing, the company has not really done it for shareholders, unless you were particularly smart/lucky with timing. I'm awaiting (possibly in vain) another favorable entry point to meaningfully get back into the stock. We are still to see Creo's tech earn meaningful revenues and 'hoping' (at this point it's no more than that) that those revenues the company can secure in the short-term are enough to prevent it from returning to the market for more cash. For a number of reasons, the path of organic sales growth will be long and is far from certain. The greater commercial and investor upside lies in one of its 2 robotics partners selecting CREO tech as part of their ecosystem. Such a decision likely within the next couple of years. Patience continues to be needed here. |
Posted at 10/8/2024 14:27 by 19bihas Would they need to RNS if they started working on getting creo products onto the Da Vinci system? Normally I would expect one (and would hope it would take this share price out of the doldrums), but the May 2022 RNS about the collaboration was so vague and all encompassing "it has signed a long-term, multi-year collaboration agreement with Intuitive to optimise certain Creo products to be compatible with Intuitive's robotic technology." |
Posted at 29/6/2024 10:40 by hope1815 Noticed Creo and been researching the company. It has done a Cash raise in 2023 and looking to break even in 2025. The cost savings it has given the NHS on its product seems to have been undervalued. With pressure on NHS with savings a company like CREO is well placed and the share price is low,There was a similar Welsh Company sold not long ago the founder retired selling out at a low point, that company went for 400 Million not long ago to a USA Medical firm. Happy Investing |
Posted at 04/3/2024 14:57 by someuwin New Edison Update:Creo Medical Clinical update MicroBlate Flex progresses with first robotics use Creo Medical has marked another milestone in advancing utility of its electrosurgical devices with the first use of its MicroBlate Flex device in a robotic-guided lung tissue ablation procedure (as part of an ongoing clinical study). Although not disclosed by the company, we believe this procedure was performed on Creo’s Kamaptive technology partner Intuitive Surgical’s ION bronchoscopy-focused robotics platform. Proving and expanding compatibility with robotic platforms has been an overarching goal for Creo and we see this as a notable step towards achieving this. The successful procedure also bodes well for the company’s partnership with Intuitive Surgical, which holds an estimated 57% market share in robotic surgical systems and has an installed base of 534 ION systems, indicative of the sizeable market opportunity for Creo. For reference the lung cancer therapeutic market size is estimated at $28bn in 2022 and is expected to reach c $60bn by 2032. MicroBlate Flex is a flexible, small diameter microwave ablation device designed for minimally-invasive soft tissue ablation. The device received FDA 510(k) clearance in 2021 (CE mark received in 2020) and is currently being evaluated for safety and feasibility in the treatment of lung lesions as part of a muti-site, post-market clinical study (announced in March 2023). The first-in-human procedure was performed in May 2023 by principal investigator, Professor Pallav L Shah, at the Royal Brompton Hospital in London, and this latest update marks the first robotics-assisted procedure using MicroBlate Flex. The procedure was used to ablate a 27mm cancerous nodule from a patient’s lung, in less than three minutes. Robotics-assisted procedures are a coveted goal in cancer treatment, given the greater precision rates and ability to excise small and hard-to-reach nodules and tumours using minimally invasive methods, greatly improving recovery rates and reducing hospitalisation expenses. The said procedure using MicroBlate Flex was performed in the same sitting as a diagnostic procedure, highlighting the utility of such systems in developing more efficient patient care and improving outcomes. We believe the procedure was conducted using Creo’s Kamaptive technology partner Intuitive Surgical’s ION robotics platform, with an installed base of 534 robots (including at the Royal Brompton Hospital) and 54,000 procedures conducted in 2023. Creo signed a multi-year collaboration with Intuitive Surgical in May 2022 and MicroBlate Flex’s utility with the ION robotics system appears to be the first of potential additional collaborations. Should the collaboration roll-over to include Intuitive’s da Vinci systems (installed base of 8,606 systems), the market opportunity can be materially larger. We note that Creo is entitled to milestone and royalty payments as part of the collaboration (c £1.8m licensing fee in 2023). We view this as an exciting development and await further updates from the company. |
Posted at 13/12/2023 07:14 by someuwin 13 December 2023Creo Medical Group plc ("Creo" the "Company" or the "Group") First European Speedboat(R) UltraSlim procedure marks early commercial launch Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces the initiation of its commercial launch of Speedboat(R) UltraSlim, following the completion of the design transfer to manufacturing last week. The first procedure using the device was completed in the UK. This first use of Speedboat(R) UltraSlim was for a lower Gastrointestinal ("GI") tract procedure, and comes shortly after the Company announced the UK and EU regulatory pathway had been accelerated by approximately 18 months . The Company expects the first European upper GI cases to follow soon, as well as first upper and lower GI cases in the USA, following the 510(k) clearance being received from the US Food & Drug Administration in November 2023. Speedboat(R) UltraSlim is the third device in Creo's Speedboat(R) family of products. The device is the culmination of a long programme of work to miniaturise the technology to a scale which covers all the foreseeable market applications, resulting in blanket compatibility with all commercial endoscopes accessing the vast majority of GI endoscopic procedures and significantly increasing the opportunity for more clinicians and patients to benefit from Creo's cutting-edge technology. Speedboat(R) UltraSlim is targeting the therapeutic treatment of disease in the GI tract including cancer of the Bowel, Stomach and Oesophagus as well as surgical procedures to deal with abnormalities resulting in swallowing disorders and in some cases gastric reflux. Powered by Creo's CROMA advanced energy platform, Speedboat(R) UltraSlim delivers advanced bipolar radiofrequency ("RF") energy for controlled cutting and high frequency microwave ("MW") energy for controlled coagulation of tissue in the GI tract. Craig Gulliford, Chief Executive Officer of Creo Medical, said: " This is yet another landmark moment for Creo Medical. We know what a difference this even smaller device will make in terms of broadening access to advanced energy in endoscopy for a wider pool of clinicians. Speedboat UltraSlim is compatible with all major endoscopes, meaning clinicians can bring advanced energy to their practices, allowing more patients to be treated endoscopically, which avoids surgery and the associated secondary costs and risks. We will continue the early market release to a designated early adopter programme over the coming weeks before the full market launch in early 2024, with significant demand for this product already indicated from existing and potential Speedboat users ." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
